Carbonaceous Oral Adsorbent's Effects on Progression of Chronic Kidney Disease (CAP-KD)
Carbonaceous Oral Adsorbent's Effects on Progression of Chronic Kidney Disease (CAP-KD)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Tokyo, Japan, 102-0072
- iHope International
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The subject is an outpatient.
- The subject is 20 years of age or older at the time of consent to participate in the study.
- The subject's serum creatinine value is 5.0 mg/dl or less at the time of case registration.
- The inverse serum creatinine value, calculated using measurements at four or more time points during an observation period that occurs within 48 weeks of case registration, is decreasing, on average, according to linear-regression analysis performed at the case registration center.
- The subject's blood pressure is well controlled before the initial serum creatinine measurement during the observation period.
- The subject has been treated with an ACEI and/or ARB before the initial serum creatinine measurement during the observation period.
- The subject has undergone low-protein diet therapy (> 0.8 g/kg per day) before the initial serum creatinine measurement during the observation period.
- The subject has not changed the type or dose of medication for renal failure for 4 weeks prior to case registration.
- The subject has participated in thorough consultation and has been informed as to the purpose, description, expected adverse effects, and risks of this study according to the consent form, and has voluntarily signed the informed consent form.
Exclusion Criteria:
- The subject has a passage disorder of the gastrointestinal tract.
- The subject has been treated with Kremezin within the period from the initial measurement of the serum creatinine level prior to case registration to the time of study commencement.
- The subject has rapid progressive glomerular nephritis, hydronephrosis, occlusive urinary tract injury, drug-induced nephropathy, or transplanted kidney.
- The subject has complications such as severe hepatopathy, liver cirrhosis, severe infection, class III or above New York Heart Association (NYHA) congestive heart failure, severe arrhythmia, or unstable angina.
- The subject has had cardiac infarction, cerebral infarction, or cerebral hemorrhage within the past 6 months.
- The subject presents with severe nephrotic syndrome (serum albumin < 2 g/dl).
- The subject is currently pregnant, or plans to become pregnant during the study period.
- The subject abuses alcohol.
- The subject has a body weight less than 80% or more than 160% of the standard weight {[height(m)]^2 x 22}.
- The subject has significant difficulty in controlling his/her blood sugar level within 3 months of case registration (hemoglobin [Hb]A1c > 8.0% on one occasion).
- The subject has a progressive malignant tumor.
- The subject is not available for study visits at least once per 2 months to provide urine samples.
- The subject is inappropriate for participation in the study for other reasons, as determined by an investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Death
|
|
The composite primary endpoint comprises the following events:
|
|
Doubling of serum Creatinine
|
|
Increase in serum Creatinine to 6.0 mg/dl or more
|
|
Endstage renal disease (ESRD; defined as that requiring dialysis or renal transplantation)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Occurrence of adverse events
|
|
Variation in urinary protein
|
|
Changes in Creatinine Clearance
|
|
Changes in health-related quality of life (HRQOL)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Yasushi Asano, Jichi Medical University
Publications and helpful links
General Publications
- Morita S, Fukuhara S, Akizawa T, Asano Y, Kurokawa K. Study design and methods for a clinical trial of an oral carbonaceous adsorbent used to prevent the progression of chronic kidney disease (CAP-KD). Clin Exp Nephrol. 2005 Sep;9(3):219-27. doi: 10.1007/s10157-005-0358-7.
- Akizawa T, Asano Y, Morita S, Wakita T, Onishi Y, Fukuhara S, Gejyo F, Matsuo S, Yorioka N, Kurokawa K; CAP-KD Study Group. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis. 2009 Sep;54(3):459-67. doi: 10.1053/j.ajkd.2009.05.011. Epub 2009 Jul 17. Erratum In: Am J Kidney Dis. 2010 Mar;55(3):616.
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CAP-KD ver.3
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.